omniture
logo
Search
GENOME COMPANY
Media Room

Latest News

rss

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI

* Results showed partial response being confirmed in 7 out of 42 patients * Partial response was...

2024-01-24 21:00 1308

Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial

* Positive primary endpoint result of objective response rate (ORR) from the planned interim anal...

2023-05-19 21:00 2171

Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial

SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- Genome & Company (CEO: Pae, Jisoo), a global leadi...

2023-05-19 16:00 1780

Genome and Company announces Clinical Trial Collaboration with MSD to evaluate 'GEN-001' in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients

SEOUL, South Korea, March 3, 2022 /PRNewswire/ -- Genome and Company (KOSDAQ: 314130, CEO∙CTO: Jiso...

2022-03-04 09:30 1740

Genome and Company signs second clinical trial collaboration and supply agreement (Phase 2) with Merck KGaA, Darmstadt, Germany and Pfizer for immuno-oncology microbiome study

* Genome and Company expands collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for fur...

2021-03-09 22:00 2981

Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients

SEOUL, South Korea, Feb. 24, 2021 /PRNewswire/ -- Genome & Company (314130, CEO: Jisoo Pae, Hansoo P...

2021-02-25 07:00 1969

Genome & Company announces first patient dosed in Phase 1/1b study of GEN-001, an immuno-oncology microbiome therapeutic, in combination with avelumab

* The first microbiome oncology therapeutic candidate developed by an Asia -based biotech successf...

2020-10-27 21:00 1262